PreprintAll rights reservedbioRxiv
An Immunocompetent Mouse Model of Degarelix Induced Chemical Castration to Investigate Acquired Resistance to Androgen Deprivation.
- 1University of Nebraska Medical Center
Related
- Prediction models for progression to castration-resistant prostate cancer after androgen deprivation therapy: a narrative review (2021–2026)
- Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer
- Integrating Genetic Variants and Expression Profiles of Pharmacogenes to Investigate Resistance to Antidepressant Treatment
- HDAC6 inhibition reverts docetaxel resistance in castration resistant prostate cancer
- 618 A novel preclinical mouse model to investigate IL-18-targeting therapies
BibTeX
@misc{robotham2026immunocompetent,
title = {{An Immunocompetent Mouse Model of Degarelix Induced Chemical Castration to Investigate Acquired Resistance to Androgen Deprivation.}},
author = {A. Robotham and D. Costanzo-Garvey and G. Waldron and L. M. Cook and G. Mathew},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.07.757377},
url = {https://www.biorxiv.org/content/10.64898/2026.10.07.757377v1},
}
RIS
TY - UNPB
TI - An Immunocompetent Mouse Model of Degarelix Induced Chemical Castration to Investigate Acquired Resistance to Androgen Deprivation.
AU - A. Robotham
AU - D. Costanzo-Garvey
AU - G. Waldron
AU - L. M. Cook
AU - G. Mathew
PY - 2026
DA - 2026/10/07
PB - bioRxiv
DO - 10.64898/2026.10.07.757377
UR - https://www.biorxiv.org/content/10.64898/2026.10.07.757377v1
ER -